|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2501 USD | -6.43% |
|
-18.27% | -41.85% |
| 05-23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
| 05-23 | Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation | CI |
Synthetic Biologics, Inc. announced that Steve Shallcross, the company's Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an officer and director of the company, effective immediately, for personal reasons.
| 1st Jan change | Capi. | |
|---|---|---|
| -41.85% | 4.32M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.55% | 21.96B | |
| -9.00% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
THERIVA BIOLOGICS, INC. 
